VOR on XNAS, Health Care, Vor Biopharma Inc., job postings
Measures activity, not value. Not investment advice.
Reported net profit of $1.4B but free cash flow was -$119.7M; shares up 180% in a year.
BadShort interest 12% of shares, 9.9 days to cover
GoodNew institutional positions 61, 5.5 times a year earlier
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
Industry
Biological products, (no diagnostic substances) (Health Care)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $86.7M.
31 Dec 2021RevenueNet incomeNet losstallest bar $1.7B30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$86.7M
30 Jun 2026
–
-$62.8M
31 Mar 2026
–
-$219.6M
31 Dec 2025
–
$1.7B
30 Sep 2025
–
-$812.7M
30 Jun 2025
–
-$1.6B
31 Mar 2025
–
-$32.5M
31 Dec 2024
–
-$30.7M
30 Sep 2024
–
-$27.6M
30 Jun 2024
–
-$27.8M
31 Mar 2024
–
-$30.8M
31 Dec 2023
–
-$26.3M
30 Sep 2023
–
-$33.2M
30 Jun 2023
–
-$30.0M
31 Mar 2023
–
-$28.4M
31 Dec 2022
–
-$23.9M
30 Sep 2022
–
-$23.8M
30 Jun 2022
–
-$21.7M
31 Mar 2022
–
-$22.7M
31 Dec 2021
–
-$18.3M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$1.4B
-$2.4B
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$119.7M
-$144.7M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$481.6M
$170.5M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$481.6M (net cash)
-$170.5M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
–
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
–
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+52%
154 13F filers vs 101
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
90%
55.3M shares held by 13F filers (30 Sep 2026) of 61.4M outstanding (26 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
12%
7.5M shares sold short (30 Oct 2026) of 61.4M outstanding (26 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
9.9
7.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+0.8%
7.4M shares sold short in the report before, 7.5M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
59%
59% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 53%
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
28
28 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
28 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.
Unusual now sharp changes in the last 90 days, compared with its own past
New institutional positions 61, 5.5× a year earlier
Price $19.19 on 20 Nov 2026, +180% over 12 months (12-month range $6.86 to $25.10)
Sharp change
8-K and other filings
WARN layoff notice
Insider net buying (open market). Insiders sold a net $49.4M in the last 12 months (the 12 months before: -$61.4M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.Capital spending per quarter. Capital spending $25K in the latest quarter, -90% on a year earlier.Institutional holders (13F filers). 154 13F filers reported holding it in the latest 13F quarter, +340% on a year earlier.Workers in WARN layoff notices. Workers in WARN layoff notices: 0 published in the last 12 months, -100% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: revenue per quarter, federal obligations, lobbying spend.
Quarter ended 31 Dec 2020: $1.5M; public on 15 Mar 2022
Quarter ended 31 Dec 2021: $1.2M, -21% on a year earlier; public on 15 Mar 2022
Quarter ended 31 Mar 2022: $2.0M, +72% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $5.8M, +535% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $298K, -53% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $321K, -73% on a year earlier; public on 24 Mar 2023
Quarter ended 31 Mar 2023: $94K, -95% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $399K, -93% on a year earlier; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $465K, +56% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $111K, -65% on a year earlier; public on 21 Mar 2024
Quarter ended 31 Mar 2024: $114K, +21% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $9K, -98% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $34K, -93% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $72K, -35% on a year earlier; public on 21 Mar 2025
Quarter ended 31 Mar 2025: $231K, +103% on a year earlier; public on 15 May 2025
Quarter ended 30 Jun 2025: $152K, +1589% on a year earlier; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $244K, +618% on a year earlier; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $314K, +336% on a year earlier; public on 31 Mar 2026
Quarter ended 31 Mar 2026: $48K, -79% on a year earlier; public on 14 May 2026
Quarter ended 30 Jun 2026: $120K, -21% on a year earlier; public on 12 Aug 2026
Quarter ended 30 Sep 2026: $25K, -90% on a year earlier; public on 31 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 54; public on 14 Feb 2022
31 Mar 2022 report: 56; public on 16 May 2022
30 Jun 2022 report: 47; public on 15 Aug 2022
30 Sep 2022 report: 45; public on 14 Nov 2022
31 Dec 2022 report: 54; public on 14 Feb 2023
31 Mar 2023 report: 55; public on 15 May 2023
30 Jun 2023 report: 66; public on 14 Aug 2023
30 Sep 2023 report: 57; public on 14 Nov 2023
31 Dec 2023 report: 55; public on 14 Feb 2024
31 Mar 2024 report: 65; public on 15 May 2024
30 Jun 2024 report: 68; public on 14 Aug 2024
30 Sep 2024 report: 51; public on 14 Nov 2024
31 Dec 2024 report: 51; public on 14 Feb 2025
31 Mar 2025 report: 45; public on 15 May 2025
30 Jun 2025 report: 32; public on 14 Aug 2025
30 Sep 2025 report: 35; public on 14 Nov 2025
31 Dec 2025 report: 54; public on 17 Feb 2026
31 Mar 2026 report: 78; public on 15 May 2026
30 Jun 2026 report: 101; public on 14 Aug 2026
30 Sep 2026 report: 154; public on 16 Nov 2026
Workers in WARN layoff notices
Month from 1 May 2025: 155 published
What is unusual now
Made public in the last 90 days: it saw 61 13F filers open a new position in the quarter ended 30 Sep 2026, 5.5× the same quarter last year.
Many funds opening a new position: saw 61 13F filers open a new position in the quarter ended 30 Sep 2026, 5.5× the same quarter last year Public on 16 Nov 2026.
In 12 months: 4 director or officer changes, 3 major agreements. Results releases and routine reports are left out.
Filed
What happened
Source
12 Nov 2026
Amended and restated license agreement with RemeGen Co., Ltd. adds RC298; $10M upfront plus pre-funded warrant for 2,300,000 sharesSame filing: sold shares privately
Two or more unrelated kinds of records unusual within 30 days
3 Jun 2025confirmed
Confirmed across sources Layoff notices and Short interest and volume
Vor Biopharma(VOR): filed a WARN layoff notice covering 155 workers within 30 days (Cambridge, MA), while it had 22.0M shares sold short in the 15 Sep 2025 report, 8.7× the same report last year. Two unrelated kinds of activity within 124 days.
Layoff notices: WARN layoff notice, became public on 29 May 2025
Short interest and volume: Short interest spike, became public on 28 May 2025
Short interest and volume: Short interest spike, became public on 11 Jun 2025
Short interest and volume: Short interest spike, became public on 26 Jun 2025
Short interest and volume: Short interest spike, became public on 25 Jul 2025
Short interest and volume: Short interest spike, became public on 12 Aug 2025
Short interest and volume: Short interest spike, became public on 27 Aug 2025
Short interest and volume: Short interest spike, became public on 11 Sep 2025
Short interest and volume: Short interest spike, became public on 25 Sep 2025
The 15 Sep 2025 report against the 24 reports before it.
this reportearliernormal: 1.5MSee the evidence (9 changes)
Layoff notices: WARN layoff notice became public on 29 May 2025
Vor Biopharma filed a WARN layoff notice covering 155 workers within 30 days (Cambridge, MA).
Fires on a WARN notice after 30 days without one; notices within 30 days are summed.
Short interest and volume: Short interest spike became public on 28 May 2025
Vor Biopharma had 2.8M shares sold short in the 15 May 2025 report, 21% below the same report last year.
This period
2.8M (the 15 May 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+3.9
Same report last year
3.5M
History used
1,553 days
the 15 May 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Jun 2025
Vor Biopharma had 4.2M shares sold short in the 30 May 2025 report, 1.2× the same report last year.
This period
4.2M (the 30 May 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+8.4
Same report last year
3.6M
History used
1,568 days
the 30 May 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jun 2025
Vor Biopharma had 3.2M shares sold short in the 13 Jun 2025 report, 15% below the same report last year.
This period
3.2M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+5.4
Same report last year
3.8M
History used
1,582 days
the 13 Jun 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Jul 2025
Vor Biopharma had 14.4M shares sold short in the 15 Jul 2025 report, 7.7× the same report last year.
This period
14.4M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+40.1
Same report last year
1.9M
History used
1,614 days
the 15 Jul 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Aug 2025
Vor Biopharma had 18.6M shares sold short in the 31 Jul 2025 report, 10× the same report last year.
This period
18.6M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+53.2
Same report last year
1.8M
History used
1,630 days
the 31 Jul 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Aug 2025
Vor Biopharma had 18.4M shares sold short in the 15 Aug 2025 report, 11× the same report last year.
This period
18.4M (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+52.7
Same report last year
1.7M
History used
1,645 days
the 15 Aug 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Sep 2025
Vor Biopharma had 19.8M shares sold short in the 29 Aug 2025 report, 13× the same report last year.
This period
19.8M (the 29 Aug 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
247K
How far from its usual level
+49.9
Same report last year
1.6M
History used
1,659 days
the 29 Aug 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Sep 2025
Vor Biopharma had 22.0M shares sold short in the 15 Sep 2025 report, 8.7× the same report last year.
This period
22.0M (the 15 Sep 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
306K
How far from its usual level
+45.2
Same report last year
2.5M
History used
1,676 days
the 15 Sep 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
16 Nov 2026Institutional holdings change
saw 61 13F filers open a new position in the quarter ended 30 Sep 2026, 5.5× the same quarter last year.
Same quarter last year: 11; its normal quarter is 11.
See the evidence
This period
61 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
11
Typical spread (median absolute deviation)
2.5
How far from its usual level
+13.5
Same quarter last year
11
History used
2,009 days
the quarter ended 30 Sep 20268 earlier quartersnormal: 11
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
saw 30 13F filers open a new position in the quarter ended 31 Mar 2026, 3.3× the same quarter last year.
Same quarter last year: 9; its normal quarter is 10.5.
See the evidence
This period
30 (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+6.5
Same quarter last year
9
History used
1,826 days
the quarter ended 31 Mar 20268 earlier quartersnormal: 10.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
saw 25 13F filers open a new position in the quarter ended 31 Dec 2025, 2.3× the same quarter last year.
Same quarter last year: 11; its normal quarter is 9.5.
See the evidence
This period
25 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
9.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+5.2
Same quarter last year
11
History used
1,736 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 9.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 22.0M shares sold short in the 15 Sep 2025 report, 8.7× the same report last year.
Same report last year: 2.5M; its normal report is 1.5M.
See the evidence
This period
22.0M (the 15 Sep 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
306K
How far from its usual level
+45.2
Same report last year
2.5M
History used
1,676 days
the 15 Sep 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 19.8M shares sold short in the 29 Aug 2025 report, 13× the same report last year.
Same report last year: 1.6M; its normal report is 1.5M.
See the evidence
This period
19.8M (the 29 Aug 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
247K
How far from its usual level
+49.9
Same report last year
1.6M
History used
1,659 days
the 29 Aug 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 18.4M shares sold short in the 15 Aug 2025 report, 11× the same report last year.
Same report last year: 1.7M; its normal report is 1.5M.
See the evidence
This period
18.4M (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+52.7
Same report last year
1.7M
History used
1,645 days
the 15 Aug 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 18.6M shares sold short in the 31 Jul 2025 report, 10× the same report last year.
Same report last year: 1.8M; its normal report is 1.5M.
See the evidence
This period
18.6M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+53.2
Same report last year
1.8M
History used
1,630 days
the 31 Jul 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 14.4M shares sold short in the 15 Jul 2025 report, 7.7× the same report last year.
Same report last year: 1.9M; its normal report is 1.5M.
See the evidence
This period
14.4M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+40.1
Same report last year
1.9M
History used
1,614 days
the 15 Jul 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.2M shares sold short in the 13 Jun 2025 report, 15% below the same report last year.
Same report last year: 3.8M; its normal report is 1.5M.
See the evidence
This period
3.2M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+5.4
Same report last year
3.8M
History used
1,582 days
the 13 Jun 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.2M shares sold short in the 30 May 2025 report, 1.2× the same report last year.
Same report last year: 3.6M; its normal report is 1.5M.
See the evidence
This period
4.2M (the 30 May 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+8.4
Same report last year
3.6M
History used
1,568 days
the 30 May 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
filed a WARN layoff notice covering 155 workers within 30 days (Cambridge, MA), while it had 22.0M shares sold short in the 15 Sep 2025 report, 8.7× the same report last year. Two unrelated kinds of activity within 124 days.
See the evidence (9 changes)
Layoff notices: WARN layoff notice became public on 29 May 2025
Vor Biopharma filed a WARN layoff notice covering 155 workers within 30 days (Cambridge, MA).
Fires on a WARN notice after 30 days without one; notices within 30 days are summed.
Short interest and volume: Short interest spike became public on 28 May 2025
Vor Biopharma had 2.8M shares sold short in the 15 May 2025 report, 21% below the same report last year.
This period
2.8M (the 15 May 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+3.9
Same report last year
3.5M
History used
1,553 days
the 15 May 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Jun 2025
Vor Biopharma had 4.2M shares sold short in the 30 May 2025 report, 1.2× the same report last year.
This period
4.2M (the 30 May 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+8.4
Same report last year
3.6M
History used
1,568 days
the 30 May 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jun 2025
Vor Biopharma had 3.2M shares sold short in the 13 Jun 2025 report, 15% below the same report last year.
This period
3.2M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+5.4
Same report last year
3.8M
History used
1,582 days
the 13 Jun 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Jul 2025
Vor Biopharma had 14.4M shares sold short in the 15 Jul 2025 report, 7.7× the same report last year.
This period
14.4M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+40.1
Same report last year
1.9M
History used
1,614 days
the 15 Jul 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Aug 2025
Vor Biopharma had 18.6M shares sold short in the 31 Jul 2025 report, 10× the same report last year.
This period
18.6M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+53.2
Same report last year
1.8M
History used
1,630 days
the 31 Jul 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Aug 2025
Vor Biopharma had 18.4M shares sold short in the 15 Aug 2025 report, 11× the same report last year.
This period
18.4M (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+52.7
Same report last year
1.7M
History used
1,645 days
the 15 Aug 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Sep 2025
Vor Biopharma had 19.8M shares sold short in the 29 Aug 2025 report, 13× the same report last year.
This period
19.8M (the 29 Aug 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
247K
How far from its usual level
+49.9
Same report last year
1.6M
History used
1,659 days
the 29 Aug 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Sep 2025
Vor Biopharma had 22.0M shares sold short in the 15 Sep 2025 report, 8.7× the same report last year.
This period
22.0M (the 15 Sep 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
306K
How far from its usual level
+45.2
Same report last year
2.5M
History used
1,676 days
the 15 Sep 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
29 May 2025Layoff notices change
filed a WARN layoff notice covering 155 workers within 30 days (Cambridge, MA).
had 2.8M shares sold short in the 15 May 2025 report, 21% below the same report last year.
Same report last year: 3.5M; its normal report is 1.5M.
See the evidence
This period
2.8M (the 15 May 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+3.9
Same report last year
3.5M
History used
1,553 days
the 15 May 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 56 entries; narrow the window or the kind of data to see older ones.
Not listed: 76 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001817229
Ticker
VOR
Domain
vorbio.com
Employer name
Vor Biopharma, Inc. (1 unverified)
Hq location
MA|BOSTON|02116 (1 unverified)
Name
Vor Biopharma Inc.
DOL H-1B labor condition applications and PERM certifications127 data points11 May 2020 to 9 Jun 2025
SEC Form 13F institutional holdings207 data points31 Mar 2021 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)78 records10 Jul 2020 to 12 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)380 data points31 Dec 2019 to 26 Oct 2026
SEC Form 4 insider transactions32 records, 112 data points9 Feb 2021 to 21 Jul 2026
FINRA short interest (twice monthly)410 data points12 Feb 2021 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2912 data points5 Feb 2021 to 20 Nov 2026
WARN layoff notices (state labor agencies)1 record, 3 data points26 May 2025 to 28 May 2025